---
title: "Top Johnson & Johnson Executive Makes Major Stock Move"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/298086145.md"
description: "Johnson & Johnson Executive Timothy Schmid sold 33,597 shares worth $9.23 million on Sept 4, 2026. Meanwhile, JNJ shares gained sentiment from positive data on its Aquyre Biopsy Scanner pilot study, highlighting workflow improvements in lung biopsies. TipRanks’ AI Analyst Spark rates JNJ as an 'Outperform', citing strong financial quality and raised guidance, despite premium valuation and headwinds from STELARA declines."
datetime: "2026-09-05T02:09:55.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/298086145.md)
  - [en](https://longbridge.com/en/news/298086145.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/298086145.md)
generator: "portal-rs"
---

# Top Johnson & Johnson Executive Makes Major Stock Move

New insider activity at Johnson & Johnson ( (JNJ) ) has taken place on September 4, 2026.

Timothy Schmid, EVP and Worldwide Chair of MedTech at Johnson & Johnson, has executed a notable stock transaction, selling 33,597 shares of Johnson & Johnson. This sale amounts to a total value of $9,230,439, highlighting a sizable move by a key executive within the company.

Johnson & Johnson shares saw sentiment supported as the company reported completion and fresh data from its pilot study of the Aquyre Biopsy Scanner for lung and lymph node biopsies. The update highlighted potential workflow gains in bronchoscopy, such as faster adequacy checks and fewer repeat procedures, which investors view as strengthening JNJ’s lung cancer ecosystem.

Analysts focused on how real‑world performance of the scanner could drive hospital adoption, reinforce JNJ’s position in interventional pulmonology, and support longer‑term revenue in minimally invasive lung care. These strategic implications, rather than short‑term earnings, underpinned recent adjustments to valuation views and near‑term expectations for the stock’s trajectory.

**Spark’s Take on JNJ Stock**

According to Spark, TipRanks’ AI Analyst, JNJ is a Outperform.

The score is driven primarily by strong financial quality (high margins, low leverage, solid free cash flow) and a generally upbeat earnings outlook with raised guidance and improving margin expectations. Offsetting factors are a premium valuation (high P/E), mixed near-term technical momentum, and notable business headwinds led by the sharp STELARA decline and pockets of MedTech softness.

To see Spark’s full report on JNJ stock,  
 click here. 

**More about Johnson & Johnson**

**YTD Price Performance:** 36.71%

**Average Trading Volume:** 7,848,252

**Technical Sentiment Signal:** Buy

**Current Market Cap:** $663.2B

### Related Stocks

- [JNJ.US](https://longbridge.com/en/quote/JNJ.US.md)

## Related News & Research

- [BREAKINGVIEWS-Smith & Nephew fix requires bigger surgery](https://longbridge.com/en/news/304107667.md)
- [Smith & Nephew merger talks with J&J orthopaedics unit collapse over CEO role, FT reports](https://longbridge.com/en/news/302831211.md)
- [Visa (V) Just Gave Investors Something To Think About](https://longbridge.com/en/news/304838789.md)
- [Is Corning (GLW) Undervalued After Strong Earnings And Higher Guidance?](https://longbridge.com/en/news/304790245.md)
- [Citi Downgraded Adobe Stock to Sell. I'd Buy It Now.](https://longbridge.com/en/news/304827167.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**